The price of Avantor Inc. (NYSE:AVTR) shares last traded on Wall Street fell -4.77% to $22.35.
AVTR stock price is now -9.35% away from the 50-day moving average and -1.31% away from the 200-day moving average. The market capitalization of the company currently stands at $15.18B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $19.50 to $26, Evercore ISI Upgraded its rating from In-line to Outperform for Avantor Inc. (NYSE: AVTR). On December 11, 2023, TD Cowen Upgraded its previous ‘Market Perform’ rating to ‘Outperform’ on the stock increasing its target price from $21 to quote $28, while ‘Bernstein’ rates the stock as ‘Mkt Perform’
In other news, Eck Steven W, SVP & Chief Accounting Officer sold 3,685 shares of the company’s stock on Mar 08 ’24. The stock was sold for $94,447 at an average price of $25.63. Upon completion of the transaction, the SVP & Chief Accounting Officer now directly owns 34,406 shares in the company, valued at $0.77 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 29 ’24, EVP, AMEA Couturier Christophe sold 13,074 shares of the business’s stock. A total of $320,705 was realized by selling the stock at an average price of $24.53. This leaves the insider owning 83,889 shares of the company worth $1.87 million. A total of 2.57% of the company’s stock is owned by insiders.
During the past 12 months, Avantor Inc. has had a low of $16.63 and a high of $26.16. As of last week, the company has a debt-to-equity ratio of 1.00, a current ratio of 1.61, and a quick ratio of 1.05. According to the stock market information, the enterprise value for the company is $21012480000, which is based on a 58.42 price-to-earnings ratio, a 6.64 price-to-earnings-growth ratio, and a beta of 1.35. The fifty day moving average price for AVTR is $24.6562 and a two-hundred day moving average price translates $22.64705 for the stock.
The latest earnings results from Avantor Inc. (NYSE: AVTR) was released for 2024-03-31. The net profit margin was 3.79% and return on equity was 5.03% for AVTR. The company reported revenue of $1.68 billion for the quarter, compared to $1.78 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.65 percent.
Avantor Inc.(AVTR) Company Profile
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
